Literature DB >> 10791241

Postoperative results of left upper abdominal evisceration for advanced gastric cancer.

Y Yonemura1, T Kawamura, N Nojima, E Bandou, T Keizou, H Fujita, Y Michiwa, T Fujimura, S Fushida, H Ajisaka, K Miwa.   

Abstract

BACKGROUND/AIMS: In spite of the improvement of surgical techniques, the prognosis of patients with advanced gastric cancer still remains poor. With the aim of achieving en bloc resection of primary tumor, peritoneal dissemination on the greater omentum and lymph node metastasis, left upper abdominal evisceration (LUAE) was performed for 75 patients. In this report, we investigated the prognostic difference between the LUAE group and standard gastrectomy (total gastrectomy + pancreatosplenectomy).
METHODOLOGY: In the LUAE group, total gastrectomy was performed with the en bloc resection of the transverse colon, pancreas body and tail, spleen and left adrenal gland. In addition, omental bursa, covering retroperitoneum and pancreas body and tail was resected in combination with greater omentum, transverse mesocolon, and lesser omentum.
RESULTS: There were 3 (4.1%) postoperative death in the LUAE group, and 2 (1.7%) in the control group. However, there was no statistical difference in the incidence of postoperative complications between these 2 groups. The overall 5-year survival rates of the LUAE and control groups were 33% and 39%, respectively. There was no statistical survival difference between these 2 groups. Survival difference between the LUAE and control group was not found in terms of tumor location, wall invasion, lymph node status, peritoneal dissemination, and macroscopic type.
CONCLUSIONS: From these results, LUAE cannot improve the survival of patients with advanced gastric cancer. Consequently, LUAE should be indicated for T4 tumors, which directly invade into the transverse colon.

Entities:  

Mesh:

Year:  2000        PMID: 10791241

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  7 in total

Review 1.  Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.

Authors:  Hassan-Alaa-Hammed Al-Shammaa; Yan Li; Yutaka Yonemura
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

2.  Higher morbidity and mortality after combined total gastrectomy and pancreaticosplenectomy for gastric cancer.

Authors:  Su-Shun Lo; Chew-Wun Wu; King-Han Shen; Mao-Chie Hsieh; Wing-Yiu Lui
Journal:  World J Surg       Date:  2002-03-26       Impact factor: 3.352

3.  Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer.

Authors:  Jason J Hall; Brian W Loggie; Perry Shen; Staci Beamer; L Douglas Case; Richard McQuellon; Kim R Geisinger; Edward A Levine
Journal:  J Gastrointest Surg       Date:  2004 May-Jun       Impact factor: 3.452

4.  Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination.

Authors:  Takahisa Yamaguchi; Sachio Fushida; Yasuhiko Yamamoto; Tomoya Tsukada; Jun Kinoshita; Katsunobu Oyama; Tomoharu Miyashita; Hidehiro Tajima; Itasu Ninomiya; Seiichi Munesue; Ai Harashima; Shinichi Harada; Hiroshi Yamamoto; Tetsuo Ohta
Journal:  Gastric Cancer       Date:  2015-11-30       Impact factor: 7.370

5.  Importance of human peritoneal mesothelial cells in the progression, fibrosis, and control of gastric cancer: inhibition of growth and fibrosis by tranilast.

Authors:  Hiroto Saito; Sachio Fushida; Shinichi Harada; Tomoharu Miyashita; Katsunobu Oyama; Takahisa Yamaguchi; Tomoya Tsukada; Jun Kinoshita; Hidehiro Tajima; Itasu Ninomiya; Tetsuo Ohta
Journal:  Gastric Cancer       Date:  2017-05-24       Impact factor: 7.370

6.  Low-dose paclitaxel modulates tumour fibrosis in gastric cancer.

Authors:  Tomoya Tsukada; Sachio Fushida; Shinichi Harada; Shiroh Terai; Yasumichi Yagi; Jun Kinoshita; Katsunobu Oyama; Hidehiro Tajima; Itasu Ninomiya; Takashi Fujimura; Tetsuo Ohta
Journal:  Int J Oncol       Date:  2013-01-29       Impact factor: 5.650

7.  Low-dose eribulin mesylate exerts antitumor effects in gastric cancer by inhibiting fibrosis via the suppression of epithelial-mesenchymal transition and acts synergistically with 5-fluorouracil.

Authors:  Toru Kurata; Sachio Fushida; Jun Kinoshita; Katsunobu Oyama; Takahisa Yamaguchi; Mitsuyoshi Okazaki; Tomoharu Miyashita; Hidehiro Tajima; Itasu Ninomiya; Tetsuo Ohta
Journal:  Cancer Manag Res       Date:  2018-08-15       Impact factor: 3.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.